α-PHP (Alpha-Pyrrolidinohexanophenone): Complete Toxicology, Dependence & Safety Monograph

α-PHP (Alpha-Pyrrolidinohexanophenone): Complete Toxicology, Dependence & Safety Monograph

Emergency stimulant toxicity: Severe agitation or confusion, seizure, dangerous overheating, chest pain, collapse, very fast/irregular heartbeat, severe weakness, or behavior that cannot be kept safely controlled after an unknown stimulant can represent a medical emergency.

Quick answer

α-PHP is alpha-pyrrolidinohexanophenone, a potent pyrrolidinophenone synthetic cathinone in the same broad stimulant family as α-PVP and α-PiHP.

Its risk profile is much better supported than the phrase “research chemical” implies.

Human and forensic evidence documents:

• severe stimulant intoxication;
• paranoia and psychotic/agitated states;
• cardiovascular toxicity;
• neurologic complications;
• fatalities;
• a persistent analytical problem distinguishing α-PHP from its positional isomer α-PiHP.

The exact human pharmacokinetic and concentration-response picture remains much less certain than the toxicology signal.

Identity

History

α-PHP belongs to the pyrovalerone/α-PVP lineage of synthetic cathinones.

The modern illicit-market signal became prominent in the mid-2010s. Review literature places α-PHP in the Japanese NPS market by about 2014, followed by European and North American forensic detections.

Its later international and U.S. scheduling reflects a sequence familiar across cathinones:

1. online/research-chemical availability;
2. poisonings and forensic detections;
3. fatalities;
4. international review;
5. national/international control.

Relationship to α-PVP and α-PiHP

α-PHP vs α-PVP

Both are pyrrolidinophenone stimulants, but α-PHP has a longer alkyl chain.

That structural change can alter:

• transporter potency;
• lipophilicity;
• metabolism;
• duration.

It does not create a reliable human dose conversion.

α-PHP vs α-PiHP

α-PHP and α-PiHP are constitutional/positional isomers with the same molecular formula.

This creates a major forensic problem.

A laboratory can misidentify the drug if its analytical method does not chromatographically separate the isomers.

The 2026 forensic case series makes this issue explicit.

Pharmacology

α-PHP behaves as a powerful psychostimulant in the pyrrolidinophenone class.

The major functional pathways involve monoamine transporters, especially:

• dopamine;
• norepinephrine.

This profile is consistent with:

• wakefulness;
• euphoria/reinforcement;
• tachycardia;
• hypertension;
• repetitive behavior;
• agitation;
• paranoia and psychosis.

Abuse liability

WHO's dependence review found strong evidence from related experimental models that α-PHP has high abuse potential.

Animal studies demonstrate:

• reinforcing effects;
• stimulant-like discrimination;
• self-administration/abuse-liability signals.

Those studies support concern but do not tell us what percentage of humans will develop stimulant use disorder.

Human clinical poisoning evidence

A 2025 translational study reviewed seven intentional nonfatal α-PHP poisonings recorded by the Pavia Poison Control Centre from 2019–2024.

Most real-world intoxications were polysubstance.

That is important because the human syndrome can reflect:

• α-PHP;
• other stimulants;
• sedatives;
• cannabinoids;
• alcohol;
• combinations.

Still, the clinical evidence reinforces that α-PHP is not merely a seized-powder chemistry finding.

Acute stimulant toxicity

Reported concerns include:

• severe agitation;
• anxiety/panic;
• paranoia;
• hallucinations;
• stimulant-induced psychosis;
• tachycardia;
• hypertension;
• chest pain;
• hyperthermia;
• seizures;
• altered consciousness;
• cardiovascular collapse.

Secondary harms can include:

• dehydration;
• rhabdomyolysis;
• kidney injury;
• trauma;
• sleep-deprivation psychiatric deterioration.

Psychosis and delirium

Pyrrolidinophenone stimulants can produce severe:

• paranoia;
• hallucinations;
• disorganized thinking;
• agitated delirium-like presentations.

Risk can be amplified by:

• repeated exposure/bingeing;
• sleep deprivation;
• stimulant combinations;
• psychiatric vulnerability.

The clinically useful description is stimulant-induced psychosis/delirium when criteria are met—not sensational labels.

Cardiovascular risk

α-PHP can create substantial sympathetic activation.

Potential complications include:

• marked tachycardia;
• hypertension;
• arrhythmia;
• myocardial stress;
• collapse.

No validated blood concentration separates “safe” from “dangerous.”

Fatalities

Fatal α-PHP intoxications are documented in the forensic literature and summarized in systematic/review sources.

Some fatalities involve other substances.

Therefore every death needs case-by-case interpretation.

The existence of mixed cases does not erase α-PHP toxicity; it simply prevents a simplistic “fatal level” claim.

Concentration does not equal clinical severity

Blood concentrations can overlap between:

• impaired-driving cases;
• nonfatal intoxications;
• fatalities.

Reasons include:

• timing;
• tolerance;
• route;
• postmortem change;
• co-drugs;
• individual physiology.

A concentration should never be translated into a personal dose or mortality prediction.

Metabolism

A 2018 human-liver metabolism study found that α-PHP forms:

• hydroxy metabolites;
• a lactam;
• keto-related products;
• carboxylic-acid products associated with the longer alkyl chain.

CYP involvement

The initial metabolic steps involved several cytochrome P450 enzymes.

For α-PHP, major modeled contributors included:

• CYP1A2;
• CYP2C9;
• CYP2C19.

This is useful mechanistic information, but controlled human interaction studies remain sparse.

Pharmacokinetics

Human α-PHP pharmacokinetic data are limited.

Published literature contains estimates from case/toxicokinetic contexts, but there is no large controlled human PK program establishing a universal:

• bioavailability;
• half-life;
• accumulation curve;
• toxic threshold.

Therefore a single reported duration or half-life should not be used as a redosing or “time until safe” clock.

Drug testing

Routine immunoassays

Standard amphetamine/MDMA immunoassays were not designed to cover the full synthetic-cathinone market.

Recent work highlights under-detection and inconsistent cross-reactivity for cathinones.

A negative routine stimulant screen does not reliably rule out α-PHP.

Definitive testing

Reliable identification may require:

• LC-MS/MS;
• LC-HRMS;
• GC-MS with appropriate separation;
• validated retention-time/reference-standard matching.

The α-PHP/α-PiHP isomer problem

This deserves its own forensic rule:

If the method cannot separate α-PHP from α-PiHP, the result should not be presented as certain molecular identity.

The 2026 forensic series emphasized chromatographic resolution.

This matters because incorrect isomer naming can distort:

• death statistics;
• concentration ranges;
• legal attribution;
• epidemiology.

Interactions

No controlled α-PHP interaction program maps safe combinations.

Important concerns include:

• other stimulants → greater cardiovascular/hyperthermic stress;
• MAO inhibitors → potentially dangerous catecholaminergic amplification;
• alcohol/benzodiazepines → impaired judgment and masking of stimulant toxicity;
• opioids → mixed overdose in which stimulant effects do not prevent respiratory depression.

An unknown street product can also contain an opioid unexpectedly.

Tolerance

Repeated stimulant exposure can produce tolerance to some subjective effects.

There is no validated α-PHP tolerance curve.

Crucially, diminished euphoria or stimulation does not prove equal tolerance to:

• hypertension;
• hyperthermia;
• psychosis;
• arrhythmia;
• sleep deprivation.

Tolerance can therefore contribute to escalation without making exposure safe.

Dependence and stimulant use disorder

α-PHP's strong reinforcement profile creates substantial concern for compulsive repeated use.

Human dependence incidence is not precisely quantified.

Stimulant use disorder involves features such as:

• craving;
• inability to cut down;
• compulsive use;
• repeated binges;
• continued use despite psychiatric/cardiovascular harm;
• interference with work or relationships.

Stimulant withdrawal

After heavy/repeated stimulant exposure, withdrawal can involve:

• profound fatigue;
• hypersomnia or insomnia;
• depressed mood;
• anhedonia;
• irritability;
• slowed thinking;
• increased appetite;
• craving.

The major emergency risk can be psychiatric—especially severe depression, psychosis, or suicidal thinking.

No α-PHP-specific withdrawal timeline has been validated.

Treatment and support

There is no medication approved specifically for α-PHP use disorder.

The ASAM/AAAP stimulant-use-disorder guideline identifies contingency management as a central evidence-based behavioral intervention, often alongside CBT/community-reinforcement approaches.

Clinicians may consider other treatments based on the broader stimulant-use-disorder picture.

U.S. resources:

• FindTreatment.gov
• SAMHSA National Helpline: 1-800-662-HELP (4357)

Severe psychosis, suicidality, chest pain, seizure, hyperthermia, or collapse requires urgent care.

Forensic interpretation

Detection is not impairment by itself

A positive α-PHP result establishes exposure.

It does not automatically establish:

• exact time of use;
• degree of impairment;
• cause of a crash;
• sole cause of death.

Isomer certainty matters

A result labeled α-PHP should be interpreted in light of whether the lab could distinguish α-PiHP.

No universal fatal concentration

Published fatal concentrations cannot be used as a personal lethal-dose chart.

Special populations

Controlled α-PHP data are inadequate for:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• cardiovascular disease;
• seizure disorders;
• serious psychiatric illness;
• liver/kidney disease.

Pre-existing cardiovascular or psychotic-spectrum illness plausibly increases concern, but the exact α-PHP-specific magnitude is unknown.

Legal status

United States

DEA temporarily controlled α-PHP in Schedule I beginning July 18, 2019.

A final rule permanently placed α-PHP in Schedule I effective June 1, 2022.

International

The UN Commission on Narcotic Drugs placed α-PHP in Schedule II of the 1971 Convention on Psychotropic Substances in 2020.

The decision entered into force November 3, 2020.

Myths and misconceptions

“α-PHP and α-PiHP are basically the same result in toxicology.”
False. They are distinct isomers and can require chromatographic separation.

“A negative amphetamine screen rules α-PHP out.”
False.

“Tolerance protects against cardiovascular toxicity.”
Not established.

“One fatal blood concentration tells me the lethal dose.”
False.

“Stimulant withdrawal is never medically important.”
Wrong. Psychiatric deterioration and suicidality can require urgent care.

“Schedule I tells you exactly how potent the drug is.”
No. Scheduling and pharmacologic potency are different questions.

Evidence ledger

Related evidence

• Synthetic cathinones & RC stimulants
• α-PVP
• α-PiHP
• N-Ethylhexedrone
• 3-MMC
• 4-MMC
• Substance Use, Dependence & Harm Reduction hub

Bottom line

α-PHP is a well-established high-risk cathinone with real human poisonings, fatal casework, strong abuse-liability evidence, and an unusually important forensic isomer problem.

A trustworthy page should not reduce it to “α-PVP with one more carbon.”

The useful safety picture is broader: stimulant psychosis, cardiovascular stress, compulsive use, imperfect routine testing, and the need to prove whether a toxicology result is truly α-PHP rather than α-PiHP.